Valuation: Alkermes plc

Market Cap 8.3B 7.17B 6.75B 6.13B 11.53B 795B 11.7B 79.13B 31.01B 398B 31.17B 30.49B 1,325B P/E 2026 *
-97x
P/E 2027 * 68.1x
Enterprise Value 9.04B 7.81B 7.35B 6.68B 12.56B 867B 12.75B 86.22B 33.79B 433B 33.96B 33.22B 1,444B EV / Sales 2026 *
4.96x
EV / Sales 2027 * 4.61x
Free-Float
89.44%
Yield 2026 *
-
Yield 2027 * -
1 day-0.74%
1 week+0.55%
Current month+1.00%
1 month-6.15%
3 months+33.05%
6 months+54.53%
Current year+76.84%
1 week 48.62
Extreme 48.62
51.66
1 month 47.66
Extreme 47.66
53.88
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
8/5/26 A Free

Chief Executive Officer

217,534 0.1297%
8/3/26 A Sell

Compliance Officer

-2,034 0.0012%
8/3/26 A Fiscal year

Chief Technology Officer

19,000 0.0113%
Change 5-day change 1-year change 3-year change Capi.($)
-0.74%+0.55%+75.99%+68.99% 8.36B
-0.11%-1.67%+1.80%+19.90% 48.84B
+1.89%+5.08%+492.59%+629.24% 45.44B
+1.83%+2.75%+15.61%+91.22% 41.22B
-0.50%-1.56%+24.67%+12.17% 39.71B
-2.74%-7.13%+18.72%+49.04% 32.6B
+0.59%-2.25% - - 16.25B
-1.14%-2.51%+27.52%+136.42% 16.67B
-0.49%-0.34%+3.45%+29.14% 14.08B
-2.60%-1.00%+77.85%+40.37% 13.68B
Average -0.40%-0.71%+82.02%+119.61% 27.69B
Weighted average by Cap. -0.04%-0.37%+103.27%+150.50%

Financials

2026 *2027 *
Net sales 1.82B 1.58B 1.48B 1.35B 2.54B 175B 2.57B 17.4B 6.82B 87.45B 6.85B 6.7B 291B 1.94B 1.68B 1.58B 1.44B 2.7B 186B 2.74B 18.54B 7.27B 93.2B 7.3B 7.14B 310B
Net income -89.92M -77.66M -73.07M -66.41M -125M -8.62B -127M -857M -336M -4.31B -338M -330M -14.35B 120M 104M 97.75M 88.84M 167M 11.53B 170M 1.15B 449M 5.76B 452M 442M 19.2B
Net Debt 744M 643M 605M 549M 1.03B 71.28B 1.05B 7.09B 2.78B 35.65B 2.79B 2.73B 119B 670M 579M 544M 495M 931M 64.19B 944M 6.39B 2.5B 32.1B 2.52B 2.46B 107B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
18/08/26 $49.48 -0.74% 970,917
17/08/26 $49.85 +1.61% 764,040
14/08/26 $49.06 -0.79% 1,267,828
13/08/26 $49.45 -1.65% 1,546,632
12/08/26 $50.28 +2.17% 1,315,646
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
49.48USD
Average target price
56.00USD
Spread / Average Target
+13.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock